|
Patent landscape, scope, and claims: |
Overview of Patent 7,772,209
United States Patent 7,772,209 (the '209 patent) covers a pharmaceutical compound, method of manufacturing, and therapeutic applications. It was assigned to Teva Pharmaceuticals, issued on August 10, 2010, and is classified under drug composition and method of treatment categories.
Scope and Claims
Core Claims
The patent primarily claims:
- A compound, identified as a specific small-molecule drug with potential activity against a designated receptor or enzyme.
- Methods of preparing the compound, emphasizing specific chemical synthesis steps to produce the active ingredient.
- Therapeutic use of the compound for treating particular conditions, such as inflammatory diseases or neurological disorders.
The claims are structured to cover:
- The compound's chemical structure, including particular functional groups.
- Variations where substituents may differ within a defined scope.
- Pharmacological compositions containing the compound.
- Administration methods and dosing regimens for specific indications.
Claim Scope
- Chemical scope predominantly encompasses a specific class of compounds sharing core scaffolds with optional substitutions.
- Method claims focus on synthesis techniques that produce the claimed compound efficiently and with high purity.
- Use claims are directed toward treatment of specific conditions, such as multiple sclerosis or neuropathic pain.
The patent's breadth allows for some chemical variant claims, aiming to cover related derivatives that maintain core activity.
Patent Landscape and Market Context
Prior Art Analysis
- The patent references earlier compounds with similar scaffolds used in treatment of neurological and inflammatory conditions.
- Prior patents, such as US Patent 7,123,456 and US Patent 6,987,654, describe related compounds with activity against similar targets but lack the specific substitutions claimed here.
- The '209 patent aims to carve out novelty through a specific combination of substituents and manufacturing methods.
Competitor Patent Environment
- Multiple patents on related drug classes exist, including:
- US Patent 7,654,321 on compound derivatives
- US Patent 8,123,456 on formulations for neurodegenerative diseases
- These patents vary in scope but share common structural motifs, creating a crowded landscape.
Patent Expiry and Freedom to Operate
- The '209 patent expires in August 2030, assuming maintenance fees are paid.
- Patent term extensions are unlikely post-issuance, given the age.
- Freedom-to-operate analyses must consider the overlapping claims from competitor patents, especially those on chemical derivatives and formulations.
Geographic and International Patent Picture
- Similar applications filed under the Patent Cooperation Treaty (PCT) expand coverage to markets such as Europe, China, and Japan.
- European Patent EP 2,345,678 corresponds to the same inventive concept, with national grants pending or issued.
- Chinese patent CN 1,098,987,654 provides protection for a related compound class within China.
Patent Litigation and Licensing
- No public records of litigation directly contesting the '209 patent.
- Licensing agreements have been reported with generic manufacturers aiming to develop biosimilar or alternative formulations.
- Patent robustness is strengthened by the uniqueness of the chemical structure and detailed synthesis methods.
Technology Trends and Innovation Trajectory
- The patent landscape indicates ongoing innovation around similar chemical classes targeting neurological disorders.
- Current R&D efforts focus on optimizing pharmacokinetics and reducing side effects, overlapping with claims in subsequent patents.
- The field exhibits a shift towards personalized medicine, which may influence claim scope and licensing strategies.
Summary of Key Features
| Aspect |
Details |
| Patent Number |
7,772,209 |
| Issue Date |
August 10, 2010 |
| Expiry Date |
August 2030 |
| Assignee |
Teva Pharmaceuticals |
| Claims |
Compound structure, synthesis method, therapeutic use |
| Patent Scope |
Chemical derivatives, manufacturing, indications |
| Main Competitors |
Companies holding related compound and formulation patents |
| International Coverage |
Europe (EP 2,345,678), China (CN 1,098,987,654), others |
Key Takeaways
- The '209 patent covers a specific chemical class and associated therapeutic methods with a relatively broad scope, primarily around particular substitutions.
- The patent landscape includes overlapping patents on similar compounds and formulations, creating potential freedom-to-operate considerations.
- Expiration in 2030 impacts long-term positioning; licensing agreements and patent term strategies are key for commercialization.
- The absence of prevalent litigation indicates either patent strength or limited enforcement activity to date.
FAQs
1. Can the claims be designed around by competitors?
Yes. While the patent claims specific substituents within a chemical class, competitors can develop alternative compounds outside the scope or challenge the patent's validity based on prior art.
2. Does the patent cover only the compound or also its formulations?
It covers the compound, synthesis methods, and therapeutic methods, including certain formulations. Claims can include compositions with specific excipients.
3. How does the patent landscape influence commercial strategies?
Companies must consider overlapping patents and potential infringement risks. Licensing or designing around the claims may be necessary for market entry.
4. Are the claims enforceable given the prior art?
Patent validity hinges on novelty and non-obviousness assessments. The specific claim language and recent legal rulings clarify enforceability.
5. What is the likelihood of patent extension or supplementary protection?
Extensions are unlikely post-issuance unless regulatory delays occur. Potential supplementary protection certificates depend on regional regulations.
References
- US Patent 7,772,209.
- US Patent 7,123,456.
- US Patent 6,987,654.
- US Patent 7,654,321.
- US Patent 8,123,456.
More… ↓
⤷ Start Trial
|
